Malignant peritoneal neoplasm+2
Not recruitingStudy of Pembrolizumab for Patients with Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Study of Pembrolizumab for Patients with Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- Disease:Malignant peritoneal neoplasmFallopian tube cancer+1
- Substances:Pembrolizumab
Italy- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS







